Updated hourlyHourly refreshSun, Oct 25, 2026
Healthcare · Biotech & pharma
Hong Kong, Oct 23, 2026 - HighTide Therapeutics, Inc. (02511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new preclinical findings for HTD1801 in autosomal dominant polycystic kidney disease (ADPKD) at Kidney Week 2026, the 59th Annual Meeting of the American Society of Nephrology (ASN), in Denver, US. The findings demonstrate potent inhibitory activity of HTD1801 against cyst expansion in ADPKD.
ADPKD is the most common inherited kidney disorder, characterized by progressive cyst formation and kidney failure by age 60 in approximately 50% of patients. Although existing treatments are available to slow disease progression in certain patients, safety risks and eligibility limitations leave substantial unmet medical needs in ADPKD. HTD1801 targets the AMPK–NLRP3 axis by activating AMPK, suppressing cAMP-driven epithelial cyst proliferation while inhibiting NLRP3 to mitigate renal inflammation and fibrotic remodeling, thereby potentially targeting key pathological processes in ADPKD.
In this study, the effect of HTD1801 on forskolin (FSK)-induced cyst expansion was evaluated in PKD1−/− human iPSC-derived nephron organoids, with metformin and tolvaptan as reference comparators. The results showed that HTD1801 significantly reduced the median cystic area fraction to 10.70%, compared with 20.40% in the FSK model control group. Meanwhile, organoids with a low cystic burden (<20%) increased from 46.9% in the model control group to 97.3%, while organoids with a high cystic burden (≥30%) decreased from 8.2% to 0%. By comparison, metformin reduced the median cystic area fraction to 13.12%, while tolvaptan did not alter cyst burden, as this model does not respond to tolvaptan.
These findings further expand the potential multidimensional renal benefits of HTD1801. Previous studies have demonstrated the potential of HTD1801 to improve metabolic abnormality-associated renal impairment. HTD1801 effectively suppresses cyst expansion in PKD1-mutant human nephron organoids, validating its dual effects of AMPK activation and NLRP3 inhibition in ADPKD pathogenesis. These preclinical findings provide a strong rationale for further clinical investigation of HTD1801 to explore its potential as a disease-modifying therapy for ADPKD. They further highlight the therapeutic potential of HTD1801 for patients with ADPKD and other chronic kidney diseases (CKD), particularly those currently underserved by existing treatment options.
Presentation Title: HTD1801 Suppresses Cyst Expansion in PKD1-Mutant Nephron Organoids: Evidence for AMPK-NLRP3 Axis Efficacy in ADPKD
Presentation Number: TH-PO0204
Date and Time: October 22, 2026, 10:00 AM–12:00 PM MDT
Format: Poster Presentation
Session: ADPKD and Cystic Kidney Disease – 1 [PO1201-1]
Presenter: Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics
“ADPKD continues to pose a substantial unmet medical need, as progressive cyst growth can lead to deterioration of kidney function and ultimately kidney failure, underscoring the need for effective therapies that can inhibit cyst growth,” said Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics. “The significant suppression of cyst expansion observed with HTD1801 in this study provides new scientific evidence to support its further development in ADPKD and highlights its potential as a disease-modifying therapy. We will continue to advance research on HTD1801 to further validate these findings and explore its potential therapeutic value in kidney diseases.”
Oct 23 · 00:30·ACN Newswire
Healthcare · Biotech & pharma
The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to...
Oct 23 · 00:02·PR Newswire
Healthcare · Biotech & pharma
SUZHOU, China, Oct. 22, 2026 -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress....
Oct 23 · 00:00·PR Newswire
Finance · Healthcare
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the pricing of its upsized initial public offering of 17,640,000 shares of its common stock at an initial public offering price of $18.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $317.5 million. All shares of common stock to be sold in the offering will be sold by Lycia. In addition, Lycia has granted the underwriters a 30-day option to purchase up to an additional 2,646,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Lycia’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 23, 2026, under the symbol “LYCA.” The offering is expected to close on October 26, 2026, subject to the satisfaction of customary closing conditions.
Oct 22 · 23:51·GlobeNewswire
Biotech & pharma
RENO, NV / October 22, 2026 / Sarcomatrix Therapeutics Corp. , a Delaware corporation based in Reno, Nevada, today reminded prospective investors that its accredited investor round, conducted under Regulation D, Rule 506(c), is scheduled to close on October 31, 2026, the closing date the company announce
Oct 22 · 23:25·ACCESS Newswire
Healthcare · Fashion & luxury
Hazlet Medical Supplies has released a guide covering Medicare Part B benefits for diabetic shoes, including eligibility criteria, annual limits, and 2026 out-of-pocket costs for NJ patients. -- New Jersey residents with diabetes who are uncertain about their footwear coverage options now have a dedicated resource from Hazlet Medical Supplies. The newly released guide addresses how Medicare Part B handles therapeutic
Oct 22 · 22:58·MarketersMEDIA
Biotech & pharma
In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD
Oct 22 · 22:40·GlobeNewswire
Biotech & pharma
Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27% Median progression-free survival was 11.7 months...
Oct 22 · 22:05·PR Newswire
Healthcare · Food & drink
BOSTON, MA and RAPPERSWIL-JONA, SWITZERLAND - October 22, 2026 - Neovii Pharmaceuticals AG, a Swiss-headquartered, commercial-stage biopharmaceutical company with more than four decades of experience in antibody-based immunotherapies, today announced that it is advancing its Type 1 Diabetes (T1D) clinical program through a company-sponsored pivotal Phase 2 study in the United States and European Union. The international expansion builds on the ongoing investigator-initiated European GIRO (Grafalon in early onset) T1D study and is supported by U.S. Food and Drug Administration (FDA) Fast Track designation for anti-T-lymphocyte globulin (ATLG) for the prevention of declining C-peptide production in patients with recent-onset T1D.
Patients have already been treated in GIRO, and clinical data are being generated. The expected 12-month efficacy and safety interim analysis will provide an important near-term milestone and inform the pivotal study program. This next stage marks an important expansion beyond transplantation and reflects Neovii’s strategy to apply its expertise in immune modulation to autoimmune and immune-mediated diseases with strong biological rationale and significant unmet medical need.
In connection with this expansion, Neovii has appointed Salvatore “Salvo” Alesci, M.D., Ph.D., as Chief Medical Officer, effective October 15, 2026. Dr. Alesci will lead the company’s medical and clinical development activities, including translational medicine and regulatory strategy. He will oversee the Type 1 Diabetes program and help shape the company’s broader clinical development strategy, including the evaluation of future development opportunities.
Scientific Rationale for ATLG in Type 1 Diabetes
Type 1 Diabetes is a chronic autoimmune disease characterized by T-cell-mediated destruction of insulin-producing pancreatic beta cells. Many patients retain residual beta-cell function following diagnosis, and preserving this endogenous function remains an important therapeutic objective.
ATLG is a polyclonal anti-T-lymphocyte globulin with preferential activity against activated T cells and broader effects across T-cell populations and immune pathways involved in autoimmune responses. Published clinical proof of concept in recent-onset Type 1 Diabetes was reported by Saudek et al. in a placebo-controlled study of ATLG. Together with other clinical evidence that modulation of pathogenic T-cell responses can preserve residual beta-cell function, these findings provide a clinical and mechanistic rationale for evaluating ATLG in the ongoing GIRO T1D study and company-sponsored pivotal Phase 2 study.
ATLG has been used in transplantation medicine for more than four decades. Building on this extensive manufacturing, preclinical, and clinical experience, Neovii is now evaluating its potential role in autoimmune disease.
The investigator-initiated European GIRO T1D study and the company-sponsored pivotal Phase 2 study in the United States and the European Union are complementary components of the ATLG clinical development program. Neovii is using emerging efficacy and safety data from GIRO to inform the pivotal study and support ongoing discussions with the FDA, European regulatory authorities, and other health authorities on a potential registration pathway.
Executive Commentary
Frederic Prince, Ph.D., Chief Executive Officer of Neovii Pharmaceuticals AG, commented:
“Despite major advances in glucose monitoring and insulin delivery, Type 1 Diabetes continues to impose a substantial burden on patients. ATLG’s well-characterized activity against activated T cells, clinical proof of concept in recent-onset disease, and extensive clinical experience provide a strong foundation for its further evaluation. Building on the investigator-initiated GIRO T1D study, we are advancing a company-sponsored pivotal Phase 2 study to assess whether ATLG can preserve endogenous beta-cell function and reduce treatment burden.
"As we take this important step in expanding Neovii’s clinical development activities, I am also delighted to welcome Salvo to Neovii as our Chief Medical Officer. His expertise in endocrinology, translational medicine, and clinical development will be highly valuable as we advance our Type 1 Diabetes program and evaluate future opportunities in immune-mediated diseases.”
Salvatore Alesci, M.D., Ph.D., Chief Medical Officer of Neovii Pharmaceuticals AG, said:
“I am excited to join Neovii at this important stage in the company’s evolution and help drive its expansion into Type 1 Diabetes and other immune-mediated diseases. Despite significant advances in disease management, preservation of endogenous beta-cell function remains an important therapeutic objective in Type 1 Diabetes. ATLG provides an opportunity to rigorously evaluate a differentiated immunomodulatory approach in a randomized clinical setting.
I look forward to working with the Neovii team, investigators, patients, advocacy groups, and regulatory authorities to execute a scientifically rigorous Type 1 Diabetes development program and shape the company’s broader clinical strategy in immune-mediated diseases.”
About Salvatore Alesci, M.D., Ph.D.
Dr. Alesci is a physician-scientist and biopharmaceutical executive with combined expertise in endocrinology and immunology and more than 25 years of experience spanning translational medicine, clinical development, regulatory strategy and scientific and patient affairs. Throughout his career, he has held senior leadership roles in biotechnology and pharmaceutical organizations, leading multidisciplinary global programs from early research through late-stage clinical development.
About Neovii Pharmaceuticals AG
Neovii Pharmaceuticals AG is a Swiss-headquartered, fully integrated biopharmaceutical company focused on developing, manufacturing, and commercializing antibody-based therapy for immune-mediated diseases. The company markets Grafalon® (ATLG, formerly named as ATG-F), an anti-human T-lymphocyte immunoglobulin approved in multiple countries for transplantation-related indications; approved uses vary by country. Grafalon is manufactured at Neovii’s dedicated biotechnology manufacturing facility in the Munich area and is commercialized in more than 50 countries. Building on decades of expertise in immune modulation, Neovii is expanding its research and development activities into selected autoimmune and immune-mediated diseases with significant unmet medical need. ATLG is investigational in Type 1 Diabetes and has not been approved for this use. Nothing in this release should be interpreted as promoting ATLG for an unapproved indication.
Forward-Looking Statement
This press release contains forward-looking statements regarding Neovii’s planned clinical development activities, regulatory interactions, clinical-study design and execution, business strategy, and potential future registration pathways. These statements are based on current beliefs, expectations, and assumptions and involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Clinical development outcomes, regulatory decisions, trial initiation and enrollment, safety and efficacy findings, development timelines, manufacturing readiness, and business objectives are subject to factors beyond Neovii’s control. Fast Track designation does not guarantee that ATLG will qualify for Accelerated Approval or Priority Review, that regulatory review will be completed within any particular timeframe, or that ATLG will receive marketing approval for Type 1 Diabetes. Neovii undertakes no obligation to update these forward-looking statements except as required by applicable law.
Reference: Saudek, F., et al. The Review of Diabetic Studies, Vol. 1, No. 2, 2004.
Media contact
Neovii Pharmaceuticals AG, info@neovii.com, www.neovii.com
Oct 22 · 21:39·NewMediaWire
Finance · Healthcare
CRYSTAL LAKE, Ill., October 22, 2026--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027. Maes joins Aptar from Amco
Oct 22 · 21:30·Business Wire
Healthcare · Biotech & pharma
BALTIMORE, Oct. 22, 2026 -- A total of 42 Mercy Medical Center physicians were recognized in Baltimore magazine's November 2026 "Top Doctors" issue, representing 30 separate specialties, ranging from neurosurgery to gynecologic oncology, specifically: 2026 – MERCY MEDICAL...
Oct 22 · 21:00·PR Newswire